TRANSCODE THERAPEUTICS, INC. Capital Expenditures
TRANSCODE THERAPEUTICS, INC. (RNAZ) reported Capital Expenditures of $6.66 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-04-15
- TRANSCODE THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-12-31 was $500.00.
- TRANSCODE THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-09-30 was $12.87K, a 179.42% increase year-over-year.
- TRANSCODE THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-06-30 was $4.55K, a 74.84% decline year-over-year.
- TRANSCODE THERAPEUTICS, INC. payments to acquire property, plant, and equipment for the quarter ending 2024-03-31 was $3.84K, a 70.25% decline year-over-year.
- TRANSCODE THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $6.66K, a 69.39% decline from fiscal 2024.
- TRANSCODE THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $21.76K, a 38.89% decline from fiscal 2023.
- TRANSCODE THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $35.61K, a 64.72% decline from fiscal 2022.
- TRANSCODE THERAPEUTICS, INC. payments to acquire property, plant, and equipment for fiscal 2022 was $100.92K, a 60.40% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.66K 10-K · filed 2026-04-15 | |||
| 2024-12-31 | $500.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $13.37K derived: sum of 2 quarters · filed 2026-04-15 | $17.93K derived: sum of 3 quarters · filed 2026-04-15 | $21.76K 10-K · filed 2026-04-15 |
| 2024-09-30 | $12.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $17.43K derived: sum of 2 quarters · filed 2025-11-14 | $21.26K 10-Q · filed 2025-11-14 | $21.26K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $4.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $8.39K 10-Q · filed 2025-08-14 | $8.39K derived: sum of 3 quarters · filed 2025-08-14 | $13.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $3.84K 10-Q · filed 2025-05-14 | $3.84K derived: sum of 2 quarters · filed 2025-05-14 | $8.44K derived: sum of 3 quarters · filed 2025-05-14 | $26.55K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $4.61K derived: sum of 2 quarters · filed 2025-04-15 | $22.71K derived: sum of 3 quarters · filed 2025-04-15 | $35.61K 10-K · filed 2025-04-15 |
| 2023-09-30 | $4.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $22.71K derived: sum of 2 quarters · filed 2024-11-14 | $35.61K 10-Q · filed 2024-11-14 | $63.82K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $18.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $31.00K 10-Q · filed 2024-08-14 | $59.22K derived: sum of 3 quarters · filed 2024-08-14 | $59.22K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $12.90K 10-Q · filed 2024-05-15 | $41.11K derived: sum of 2 quarters · filed 2024-05-15 | $41.11K derived: sum of 3 quarters · filed 2024-05-15 | $83.16K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $28.21K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $28.21K derived: sum of 2 quarters · filed 2024-04-01 | $70.26K derived: sum of 3 quarters · filed 2024-04-01 | $100.92K 10-K · filed 2024-04-01 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $42.05K derived: sum of 2 quarters · filed 2023-11-14 | $72.70K 10-Q · filed 2023-11-14 | $158.43K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $42.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $72.70K 10-Q · filed 2023-08-14 | $158.43K derived: sum of 3 quarters · filed 2023-08-14 | $229.98K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $30.66K 10-Q · filed 2023-05-15 | $116.39K derived: sum of 2 quarters · filed 2023-05-15 | $187.94K derived: sum of 3 quarters · filed 2023-05-15 | $210.18K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $85.73K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $157.28K derived: sum of 2 quarters · filed 2023-03-31 | $179.52K derived: sum of 3 quarters · filed 2023-03-31 | $254.82K 10-K · filed 2023-03-31 |
| 2021-09-30 | $71.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $93.79K derived: sum of 2 quarters · filed 2022-11-14 | $169.09K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $22.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $97.54K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $75.30K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |